Latest News and Press Releases

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius...

Urges stockholders to vote “FOR” Radius’ highly qualified, independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE proxy card...

Advances asset in the neuro-endocrine orphan disease spaceSCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced30+ global sites are planned for the seamless Phase...

Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of...

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data...

Globalization has been a key priority for the Company over the past two yearsThree additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa...

FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the...

Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card...

Company ascertained regulatory clarity for possible forward progression of abalo-TDSAdditional and successful clinical trial would be required to advance towards an NDA filingNew timeline for earliest...

Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today...